1. Search Result
Search Result
Results for "

bisphosphonate

" in MCE Product Catalog:

32

Inhibitors & Agonists

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-U00145
    Digeranyl bisphosphonate

    DGBP

    Ras Inflammation/Immunology
    Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.
  • HY-108685
    Alendronate sodium

    Alendronic acid monosodium salt

    Others Metabolic Disease
    Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis.
  • HY-13777
    Zoledronic Acid

    Zoledronate; CGP 42446; CGP42446A; ZOL 446

    Apoptosis Autophagy Cancer Metabolic Disease
    Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects.
  • HY-13777A
    Zoledronic acid monohydrate

    Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate

    Apoptosis Autophagy Cancer Metabolic Disease
    Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects.
  • HY-B0631
    Alendronic acid

    Others Cancer
    Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease.
  • HY-A0213
    Tiludronate

    Tiludronic acid

    Proton Pump Inflammation/Immunology
    Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
  • HY-A0213A
    Tiludronate disodium

    Tiludronic acid disodium

    Proton Pump Inflammation/Immunology
    Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
  • HY-A0213B
    Tiludronate disodium hemihydrate

    Tiludronic acid disodium hemihydrate

    Proton Pump Metabolic Disease
    Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H +-ATPase. Antiresorptive and anti-inflammatory properties.
  • HY-13777B
    Zoledronic acid disodium tetrahydrate

    Zoledronate disodium tetrahydrate; CGP 42446 disodium tetrahydrate; CGP42446A disodium tetrahydrate; ZOL 446 disodium tetrahydrate

    Apoptosis Autophagy Cancer Metabolic Disease
    Zoledronic Acid (Zoledronate) disodium tetrahydrate is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid disodium tetrahydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid disodium tetrahydrate also has anti-cancer effects.
  • HY-B0012A
    Pamidronate Disodium

    CGP 23339A

    Others Metabolic Disease
    Pamidronate disodium, a bisphosphonate drug, can help to strengthen bones.
  • HY-B0515B
    Ibandronate Sodium

    Others Metabolic Disease
    Ibandronate Sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
  • HY-B0515A
    Ibandronic acid

    Others Cancer
    Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
  • HY-B0515
    Ibandronate Sodium Monohydrate

    BM-210955; RPR-102289A

    Apoptosis Cancer
    Ibandronate Sodium Monohydrate is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
  • HY-B0730
    Pamidronate disodium pentahydrate

    Others Others
    Pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis.
  • HY-16011
    NE 10790

    3-PEHPC

    Others Others
    NE 10790, a poor farnesyl pyrophosphate synthase inhibitor, is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent.
  • HY-118224
    BPH-715

    Parasite Infection
    BPH-715 is a bisphosphonate, inhibits Plasmodium liver-stage growth, with an IC50 of 10 μM for Plasmodium exoerythrocytic forms in HepG2 cells.
  • HY-108309
    Medronic acid

    Methylenediphosphonic acid

    Others Others
    Medronic acid (Methylenediphosphonic acid) is a methylene-substituted bisphosphonate. Medronic acid has affinity for and adheres to the surface of hydroxyapatite crystals in the bone matrix. Medronic acid accumulates at sites of osteoid mineralization and can be used, complexed with radioisotopes in bone imaging.
  • HY-107093
    MBC-11

    Others Cancer
    MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research.
  • HY-107093B
    MBC-11 triethylamine

    Others Cancer
    MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research.
  • HY-107093A
    MBC-11 trisodium

    Others Cancer
    MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research.
  • HY-B0657A
    Clodronic acid disodium salt

    Clodronate disodium salt

    Others Inflammation/Immunology
    Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active osteoclastic bone resorption inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Pagets disease and osteolytic bone metastases.
  • HY-B0657
    Clodronic acid

    Clodronate

    Others Others
    Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density.
  • HY-B0302
    Etidronic acid

    Etidronate; HEDPA; HEDP

    Apoptosis Cancer Metabolic Disease
    Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water.
  • HY-B0302A
    Etidronic acid disodium

    Etidronate disodium; HEDPA disodium; HEDP disodium

    Apoptosis Cancer Metabolic Disease
    Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water.
  • HY-16322
    Minodronic acid

    YM-529

    P2X Receptor Apoptosis Cancer
    Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain.
  • HY-A0213AS
    Tiludronate-d5 sodium

    Tiludronic acid-d5 sodium

    Proton Pump Inflammation/Immunology
    Tiludronate-d5 (Tiludronic acid-d5) sodiumis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
  • HY-101076
    L-690488

    Phosphatase Metabolic Disease
    L-690488 is a prodrug of L-690330 and is a selective inositol monophosphatase (IMPase) inhibitor. L-690488 has more effective cell penetration than L-690330.
  • HY-144130
    hGGPPS-IN-3

    Apoptosis Cancer
    hGGPPS-IN-3 (Compound 13h) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-3 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-3 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo.
  • HY-16322S
    Minodronic acid-d4

    YM-529-d4

    P2X Receptor Apoptosis Cancer
    Minodronic acid-d4 is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain.
  • HY-144129
    hGGPPS-IN-2

    Apoptosis Cancer
    hGGPPS-IN-2 (Compound 16g) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-2 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo.
  • HY-144128
    hGGPPS-IN-1

    Apoptosis Cancer
    hGGPPS-IN-1 (Compound 18b) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-1 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-1 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo.
  • HY-107794
    Clodronate disodium tetrahydrate

    Disodium clodronate tetrahydrate

    Others Inflammation/Immunology Neurological Disease
    Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl - competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain.